Potentia Wealth Invests $381,000 in GSK plc (NYSE:GSK)

Potentia Wealth purchased a new stake in shares of GSK plc (NYSE:GSK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,279 shares of the pharmaceutical company’s stock, valued at approximately $381,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dorsey & Whitney Trust CO LLC raised its holdings in shares of GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after acquiring an additional 278 shares in the last quarter. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Rehmann Capital Advisory Group raised its holdings in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares in the last quarter. GC Wealth Management RIA LLC lifted its position in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares during the period. Finally, Jacobi Capital Management LLC boosted its stake in shares of GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

GSK stock opened at $38.58 on Tuesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a 50 day moving average price of $36.77 and a 200-day moving average price of $36.84. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The firm has a market capitalization of $79.86 billion, a price-to-earnings ratio of 24.27, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities research analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.08%. GSK’s payout ratio is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.